A novel prescription

摘要

When large Western firms set up shop in China, it is generally because they plan to take advantage of low-cost manufacturing of goods that contain the minimum possible amount of intellectual property that might be stolen. But that is not the case for Novartis, the world's fourth-largest pharmaceutical company, which announced plans this week to invest $100m in a new research facility in Shanghai. Its motives are different and rather unusual.